Core Insights - Fortress Biotech, Inc. is under investigation by Holzer & Holzer, LLC for potential non-compliance with federal securities laws following the FDA's issuance of a Complete Response Letter regarding its New Drug Application for CUTX-101, citing cGMP deficiencies at the manufacturing facility [1] Company Summary - Fortress Biotech, Inc. (NASDAQ: FBIO) announced that the FDA issued a Complete Response Letter for CUTX-101, which has led to a decline in the company's stock price [1] - The Complete Response Letter indicates that there were observed deficiencies in current Good Manufacturing Practices (cGMP) at the facility where CUTX-101 is produced [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]